Pharming Group Enterprise Value Over E B I T D A Over Time
| PHAR Stock | USD 7.65 0.12 1.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pharming Group Performance and Pharming Group Correlation. Pharming |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharming Group. If investors know Pharming will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharming Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.27) | Revenue Per Share 4.38 | Quarterly Revenue Growth 0.122 | Return On Assets (0.01) |
The market value of Pharming Group NV is measured differently than its book value, which is the value of Pharming that is recorded on the company's balance sheet. Investors also form their own opinion of Pharming Group's value that differs from its market value or its book value, called intrinsic value, which is Pharming Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharming Group's market value can be influenced by many factors that don't directly affect Pharming Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharming Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharming Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharming Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Enterprise Value Over E B I T D A Analysis
Compare Pharming Group NV and related stocks such as Gelesis Holdings, Eliem Therapeutics, and Genenta Science SpA Enterprise Value Over E B I T D A Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNTA | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (26.4157) | (24.3451) | (5.7779) | (6.662) | (7.0) |
| OPT | (97.7447) | 0.0446 | (0.1917) | (0.4671) | (0.8719) | (9.1043) | (8.9109) | (3.0057) | (3.6696) | (22.1937) | (3.4862) | (1.6387) | (0.1709) | (0.582) | (0.61) |
| MLYS | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (21.1473) | (3.0938) | (3.25) |
| ANEB | (955) | (955) | (955) | (955) | (955) | (955) | (955) | (955) | (955) | (955) | (4.6039) | 19.2 K | (4.0461) | (8.2119) | (7.8) |
| JANX | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (215) | (23.7183) | (7.8496) | (6.7249) | (7.06) |
| RZLT | (5.3212) | (5.3212) | (5.3212) | (3.5973) | (3.1859) | (1.4665) | (2.2018) | (0.9547) | (0.2372) | (0.8465) | (3.6204) | 2.1861 | (1.7079) | (2.2455) | (2.36) |
| FENC | (0.6193) | 4.2629 | (4.4411) | 15.8552 | (8.4275) | (9.4934) | 283 | (1.3 K) | 188 | 493 | (8.1773) | (799) | (11.2173) | (25.5456) | (26.82) |
| LRMR | (23.7423) | (23.7423) | (23.7423) | (23.7423) | (23.7423) | (1.8947) | (1.0106) | (2.0155) | (2.1517) | (5.2652) | (4.5203) | (2.4154) | (2.4222) | (4.3079) | (4.52) |
| VRCA | (182) | (182) | (182) | (182) | (182) | (182) | (182) | (76.3739) | (1.4394) | (12.8515) | (7.9207) | (9.0847) | (2.8338) | (4.9499) | (5.2) |
| MOLN | 43.6358 | 43.6358 | 43.6358 | 43.6358 | (107) | 643 | (20.3659) | (16.8974) | (7.9868) | (8.9608) | (6.5833) | (8.0238) | 0.995 | (0.8246) | (0.78) |
| PRTC | (251) | (251) | (251) | (461) | (40.0305) | (137) | (117) | (226) | (159) | 24.3575 | 253 | (217) | (169) | (52.712) | (55.35) |
| ACRV | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (65.2905) | (16.4254) | (7.5807) | (1.2907) | (1.36) |
Pharming Group NV and related stocks such as Gelesis Holdings, Eliem Therapeutics, and Genenta Science SpA Enterprise Value Over E B I T D A description
My Equities
My Current Equities and Potential Positions
| Pharming Group NV | PHAR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Netherlands |
| Exchange | NASDAQ Exchange |
USD 7.65
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.